Overview

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Status:
Recruiting

Trial end date:
2027-09-25

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company